ALKS (Alkermes) Moat Score: 6/10 (As of Jun. 29, 2026)


ALKS Alkermes PLC ALKS
64 GF Score
Price $53.02
GF Value $31.33
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes Moat Score?

Alkermes ALKS -3.87% 64 Moat Score is 6 as of Jun. 29, 2026. GuruFocus rates ALKS with a GF Score™ of 64/100 and a GF Value™ of $31.33 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Alkermes ranks better than 97.09% on this metric.

Alkermes has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Alkermes has Narrow Moat: Alkermes PLC has a strong narrow moat due to its valuable intellectual property and consistent innovation in pharmaceuticals. It benefits from regulatory barriers and customer switching costs, but lacks the scale and brand strength for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Alkermes might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Alkermes  (NAS:ALKS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Alkermes Moat Score Related Terms

ALKS vs HIMS, LNTH, LQDA: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alkermes Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Moat Score distribution charts can be found below:

* The bar in red indicates where Alkermes's Moat Score falls into.


ALKS
64GF Score
Alkermes PLC ALKS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Alkermes (ALKS) has a Moat Score of 6 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Alkermes ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Alkermes' Moat Score too high?
Alkermes' current Moat Score is 6. Based on the distribution chart, Alkermes ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alkermes has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Moat Score compare to HIMS and LNTH?
According to the Drug Manufacturers industry distribution chart, Alkermes ranks #30 out of 1030 companies for Moat Score. This places Alkermes in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Alkermes's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.33, compared to a current price of $53.02 — trading 69.2% above its estimated fair value. The current Moat Score is 6. Alkermes' overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Alkermes (ALKS), the current Moat Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (ALKS) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of $53.02 is trading 69.2% above its estimated GF Value™ of $31.33. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for ALKS:

  • Moat Score: 6
  • GF Value™: $31.33 vs. price of $53.02 (69.2% above fair value)
  • GF Score™: 64/100 with 8 warning signs

No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkermes Business Description

Other Exchanges 8AK:Germany
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
64GF Score

Get the complete analysis for ALKS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.02
Price
$31.33
GF Value